{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:24:06Z","timestamp":1792193046024,"version":"4.4.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Annual tobacco-related death estimates are 480\u202f000 in the US and 8 million worldwide, surpassing mortality for other abused substances. Most smoking cessation interventions result in modest long-term success.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare prolonged smoking abstinence rates in smokers receiving psilocybin plus cognitive behavioral therapy (CBT) with those receiving the nicotine patch plus CBT.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this pilot randomized clinical trial, participants and investigators were unblinded to treatment condition, including an optional crossover after completion of the primary end point. Data were collected from psychiatrically healthy adult smokers from January 20, 2015, to May 8, 2023, at the Johns Hopkins Bayview Medical Center, an academic medical center and teaching hospital in Baltimore, Maryland.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n The trial randomized cigarette smokers to receive either 1 high dose (30 mg\/70 kg) of psilocybin or initiate 8 to 10 weeks of US Food and Drug Administration\u2013approved nicotine patch treatment on the target quit date. Both groups received a 13-week manualized CBT program for smoking cessation.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Biochemically verified prolonged smoking abstinence (primary) and 7-day point prevalence abstinence (secondary) at 6 months after the target quit date were compared between groups using intention-to-treat analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 82 psychiatrically healthy adult smokers (mean [SD] age, 47.6 [12.0] years; 49 [59.8%] male) participated in the study, with 68 (82.9%) completing the 6-month follow-up. At 6-month follow-up, 17 participants receiving psilocybin (40.5%) exhibited biochemically verified prolonged abstinence compared with 4 participants using the nicotine patch (10.0%) (odds ratio, 6.12; 95% CI, 1.99-23.26;\n P<\/jats:italic>\n \u2009=\u2009.003), and 22 participants receiving psilocybin (52.4%) exhibited biochemically verified 7-day point prevalence abstinence compared with 10 participants using the nicotine patch (25.0%) (odds ratio, 3.30; 95% CI, 1.32-8.70;\n P<\/jats:italic>\n \u2009=\u2009.01). No serious adverse events were attributed to psilocybin or nicotine patch.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this pilot randomized clinical trial, 1 dose of psilocybin with manualized CBT significantly increased long-term abstinence compared with nicotine patch treatment with CBT. Psilocybin abstinence rates were higher than typical treatments, suggesting promise for tobacco smoking cessation.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT01943994<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.0972","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:00:48Z","timestamp":1773154848000},"page":"e260972","source":"Crossref","is-referenced-by-count":15,"title":["Psilocybin or Nicotine Patch for Smoking Cessation"],"prefix":"10.1001","volume":"9","author":[{"given":"Matthew W.","family":"Johnson","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon P.","family":"Naud\u00e9","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Hendricks","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Garcia-Romeu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"10258","key":"zoi260062r1","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"zoi260062r3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths - United States, 2017-2018.","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"52","key":"zoi260062r4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.15585\/mmwr.mm6552a1","article-title":"Quitting smoking among adults - United States, 2000-2015.","volume":"65","author":"Babb","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"zoi260062r5","article-title":"Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.","volume":"9","author":"Lindson","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"zoi260062r6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2022.0395","article-title":"Treatment of tobacco smoking: a review.","volume":"327","author":"Rigotti","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"zoi260062r7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jama.2013.283787","article-title":"Pharmacological treatments for smoking cessation.","volume":"311","author":"Cahill","year":"2014","journal-title":"JAMA"},{"key":"zoi260062r8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-3-031-12184-5","article-title":"Classic psychedelics in addiction treatment: the case for psilocybin in tobacco smoking cessation.","volume":"56","author":"Johnson","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"issue":"6","key":"zoi260062r9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study.","volume":"28","author":"Savage","year":"1973","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"zoi260062r10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"issue":"11","key":"zoi260062r11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"1","key":"zoi260062r12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation.","volume":"43","author":"Johnson","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"zoi260062r13","doi-asserted-by":"publisher","first-page":"10578","DOI":"10.1038\/s41598-022-14809-3","article-title":"Associations between classic psychedelics and nicotine dependence in a nationally representative sample.","volume":"12","author":"Jones","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"zoi260062r14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.","volume":"31","author":"Johnson","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"3","key":"zoi260062r15","doi-asserted-by":"publisher","first-page":"47000","DOI":"10.4088\/JCP.22r14518","article-title":"Control conditions in randomized trials of psychedelics: an ACTTION systematic review.","volume":"84","author":"Nayak","year":"2023","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"zoi260062r16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000146.pub5","article-title":"Nicotine replacement therapy versus control for smoking cessation.","volume":"5","author":"Hartmann-Boyce","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"20","key":"zoi260062r17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"zoi260062r18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081124","article-title":"CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials.","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"issue":"3","key":"zoi260062r20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/heapro\/16.3.255","article-title":"Effectiveness of a cognitive behaviour therapy self-help programme for smokers in London, UK.","volume":"16","author":"Sykes","year":"2001","journal-title":"Health Promot Int"},{"issue":"2","key":"zoi260062r21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/001316444600600208","article-title":"The Shipley-Hartford Scale as an independent measure of mental ability.","volume":"6","author":"Lewinski","year":"1946","journal-title":"Educ Psychol Meas"},{"issue":"1","key":"zoi260062r22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/ntr\/ntr137","article-title":"Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence.","volume":"14","author":"Fagerstr\u00f6m","year":"2012","journal-title":"Nicotine Tob Res"},{"key":"zoi260062r23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.15288\/jsas.1994.s12.70","article-title":"Ensuring balanced distribution of prognostic factors in treatment outcome research.","volume":"12","author":"Stout","year":"1994","journal-title":"J Stud Alcohol Suppl"},{"key":"zoi260062r24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.18332\/tid\/111355","article-title":"The mobile-phone-based iCOTM Smokerlyzer\u00ae: Comparison with the piCO+ Smokerlyzer\u00ae among smokers undergoing methadone-maintained therapy.","volume":"17","author":"Wong","year":"2019","journal-title":"Tob Induc Dis"},{"issue":"1","key":"zoi260062r26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1037\/a0030992","article-title":"Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use.","volume":"28","author":"Robinson","year":"2014","journal-title":"Psychol Addict Behav"},{"issue":"5","key":"zoi260062r27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1037\/0278-6133.10.5.360","article-title":"The Contemplation Ladder: validation of a measure of readiness to consider smoking cessation.","volume":"10","author":"Biener","year":"1991","journal-title":"Health Psychol"},{"issue":"11","key":"zoi260062r28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/j.1360-0443.1991.tb01732.x","article-title":"The development and initial validation of a questionnaire on smoking urges.","volume":"86","author":"Tiffany","year":"1991","journal-title":"Br J Addict"},{"issue":"7","key":"zoi260062r29","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/ntr\/ntz132","article-title":"Biochemical verification of tobacco use and abstinence: 2019 Update.","volume":"22","author":"Benowitz","year":"2020","journal-title":"Nicotine Tob Res"},{"issue":"6","key":"zoi260062r31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/1097-4679(198511)41:6<820::AID-JCLP2270410616>3.0.CO;2-X","article-title":"Estimating WAIS IQ from the Shipley Institute of Living Scale using continuously adjusted age norms.","volume":"41","author":"Zachary","year":"1985","journal-title":"J Clin Psychol"},{"issue":"4","key":"zoi260062r32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0269881121996863","article-title":"Associations between lifetime classic psychedelic use and markers of physical health.","volume":"35","author":"Simonsson","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"6","key":"zoi260062r33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety.","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"zoi260062r34","doi-asserted-by":"crossref","DOI":"10.1177\/2050312118777953","article-title":"Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004-2016.","volume":"6","author":"Motooka","year":"2018","journal-title":"SAGE Open Med"},{"issue":"1","key":"zoi260062r35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/1574886311207040282","article-title":"Adverse effects cause varenicline discontinuation: a meta-analysis.","volume":"11","author":"Drovandi","year":"2016","journal-title":"Curr Drug Saf"},{"key":"zoi260062r36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.18332\/tid\/154075","article-title":"Electronic cigarettes versus nicotine-replacement therapy for smoking cessation: a systematic review and meta-analysis of randomized controlled trials.","volume":"20","author":"Li","year":"2022","journal-title":"Tob Induc Dis"},{"issue":"10","key":"zoi260062r37","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial.","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"zoi260062r38","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions.","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"zoi260062r39","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey.","volume":"10","author":"Garcia-Romeu","year":"2020","journal-title":"Front Psychiatry"},{"issue":"7","key":"zoi260062r40","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0269881118780612","article-title":"Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts.","volume":"32","author":"Noorani","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"4","key":"zoi260062r41","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00213-019-05445-3","article-title":"Ayahuasca\u2019s \u2018afterglow\u2019: improved mindfulness and cognitive flexibility in ayahuasca drinkers.","volume":"237","author":"Murphy-Beiner","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"zoi260062r42","doi-asserted-by":"crossref","first-page":"8833","DOI":"10.1038\/s41598-024-58318-x","article-title":"Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.","volume":"14","author":"Sloshower","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"zoi260062r43","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"1","key":"zoi260062r44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","article-title":"Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.","volume":"11","author":"Doss","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"8","key":"zoi260062r45","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1017\/S0033291723003653","article-title":"Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.","volume":"54","author":"Szigeti","year":"2024","journal-title":"Psychol Med"},{"key":"zoi260062r46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jad.2023.01.108","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life.","volume":"327","author":"Goodwin","year":"2023","journal-title":"J Affect Disord"},{"issue":"12","key":"zoi260062r47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.49026","article-title":"Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial.","volume":"7","author":"Back","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi260062r48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/appi.ajp.20221043","article-title":"Must psilocybin always \u201cassist psychotherapy\u201d?","volume":"181","author":"Goodwin","year":"2024","journal-title":"Am J Psychiatry"},{"key":"zoi260062r49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.18332\/tpc\/70088","article-title":"Effectiveness of mobile apps for smoking cessation: a review.","volume":"3","author":"Regmi","year":"2017","journal-title":"Tob Prev Cessat"},{"key":"zoi260062r19","volume-title":"Cognitive-Behavioral Therapy for Smoking Cessation: A Practical Guidebook to the Most Effective Treatments","author":"Perkins","year":"2008"},{"key":"zoi260062r25","volume-title":"Measuring Alcohol Consumption: Psychosocial and Biochemical Methods","author":"Sobell","year":"1992"},{"key":"zoi260062r2","unstructured":"Centers for Disease Control and Prevention. The Health Consequences of Smoking\u201450 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention; 2014. Accessed June 10, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK179276"},{"key":"zoi260062r30","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Published online 2024. Accessed January 21, 2026. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2846155\/johnson_2026_oi_260062_1772564464.70221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:00:54Z","timestamp":1773154854000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2846155"}},"subtitle":["A Pilot Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.0972","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}